A Phase 1 interventional study of SAR447971 and Placebo in Hidradenitis and Healthy Volunteers, sponsored by Sanofi. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Sanofi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants.
MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants.
Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20.
Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.
34 studies on the registry are indexed under Hidradenitis; 9 are open to participants now.
This study's planned enrollment of 122 is close to the median of 121 across 28 interventional studies indexed under Hidradenitis.
Browse Hidradenitis studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participation in SAD20411/MAD20412:
For participation in MAD24339:
Exclusion Criteria:
For participation in SAD20411/MAD20412:
Any history or presence of cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female) or signs of acute illness. Active or chronic infection requiring systemic treatment within 4 weeks prior to baseline. Known history of or suspected current immunosuppression.
For participation in MAD24339:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single or multiple doses by mouth as per protocol
Drug: SAR447971
Single or multiple doses by mouth as per protocol
Drug: Placebo
Pharmaceutical form: Tablet Route of administration: Oral
Also known as: KT-485
Pharmaceutical form: Tablet Route of administration: Oral
SAD20411: Incidence of treatment emergent adverse events (TEAEs)
Time frame: Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
Time frame: Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in vital signs
Time frame: Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
Time frame: Day 1 to Day 15
MAD20412: Incidence of treatment emergent adverse events (TEAEs)
Time frame: Day 1 to Day 29
MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
Time frame: Day 1 to Day 29
MAD20412: Incidence of clinically significant abnormalities in vital signs
Time frame: Day 1 to Day 29
MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
Time frame: Day 1 to Day 29
MAD24339: Incidence of treatment emergent adverse events (TEAEs)
Time frame: Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
Time frame: Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in vital signs
Time frame: Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
Time frame: Day 1 to Day 42
SAD20411: PK parameter - Cmax
Maximum serum concentration observed.
Time frame: Day 1 to Day 15
SAD20411: PK parameter - tmax
Time to reach Cmax.
Time frame: Day 1 to Day 15
SAD20411:PK parameter - AUC
Area under the plasma concentration versus time curve extrapolated to infinity.
Time frame: Day 1 to Day 15
SAD20411: PK parameter - Cmax in fed and fasted state
Maximum serum concentration observed.
Time frame: Day 1 to Day 15
SAD20411: PK parameter - tmax in fed and fasted state
Time to reach Cmax.
Time frame: Day 1 to Day 15
SAD20411: PK parameter - AUC in fed and fasted state
Area under the plasma concentration versus time curve extrapolated to infinity.
Time frame: Day 1 to Day 15
MAD20412: PK parameter - Cmax
Maximum serum concentration observed.
Time frame: Day 1 to Day 22
MAD20412: PK parameter - tmax
Time to reach Cmax.
Time frame: Day 1 to Day 22
MAD20412: PK parameter - AUC0-tau
Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval
Time frame: Day 1 to Day 22
MAD24339: IRAK4 expression in skin biopsies before and after repeated doses of SAR447971
Time frame: Day 1 to Day 42
MAD24339: Plasma SAR447971 concentrations at pre-specified visits and time points
Time frame: Day 1 to Day 42
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started May 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Feb 2028 → Apr 2028 and completion Feb 2028 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.